Moreover, mutations inhibiting the function of PTEN, which acts as a negative regulator, are also common [37]; in fact, a reduced expression of PTEN—measured by immunohistochemistry—was associated with those BC patients who showed a higher progression and recurrence of their disease [38]. The gene discussed is PTEN; the disease is breast cancer.